c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.
about
Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.Glutamate and α-ketoglutarate: key players in glioma metabolism.Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.MicroRNA-340 inhibits the proliferation and promotes the apoptosis of colon cancer cells by modulating REV3L.miR-129-5p targets Wnt5a to block PKC/ERK/NF-κB and JNK pathways in glioblastoma.New insights into acquired temozolomide resistance in glioblastoma?
P2860
c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
c-Myc-miR-29c-REV3L signalling ...... de resistance in glioblastoma.
@en
type
label
c-Myc-miR-29c-REV3L signalling ...... de resistance in glioblastoma.
@en
prefLabel
c-Myc-miR-29c-REV3L signalling ...... de resistance in glioblastoma.
@en
P2093
P2860
P356
P1433
P1476
c-Myc-miR-29c-REV3L signalling ...... de resistance in glioblastoma.
@en
P2093
Chenghao Peng
Chunsheng Zhao
Gang Cheng
Hong-Wei Wang
Huibo Wang
Jingmin Yang
P2860
P304
P356
10.1093/BRAIN/AWV287
P407
P577
2015-10-08T00:00:00Z